NDAORALFOR SOLUTION
Approved
Mar 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
ORALTAG (iohexol) by R-Pharm US is x-ray contrast activity [moa]. Approved for diabetic kidney disease, diabetic nephropathy, acute kidney injury and 20 more indications. First approved in 2015.
Drug data last refreshed 20h ago
Mechanism of Action
X-Ray Contrast Activity
Worked on ORALTAG at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.